



April 13, 2020

Re: PREempt™ efficacy against SARS-CoV-2, the virus which causes COVID-19 disease

Dear Sir or Madam,

In cases of emerging viral pathogens like SARS-CoV-2, the virus that causes COVID-19, when there is no test that can be conducted to validate the efficacy of a disinfectant against an emerging viral pathogen, Health Canada utilizes the Broad Spectrum Virucide claim to determine the expected efficacy of a disinfectant against an emerging virus. This guidance, used previously during the 2003 SARS epidemic, mandates that for disinfectant products to be approved, they must have proven efficacy against one of the following four non-enveloped viruses; Adenovirus type 5, Bovine Parvovirus, Canine Parvovirus and Poliovirus type 1.

The PREempt™ line of disinfectants (concentrate, ready-to-use and premoistened wipes) have broad-spectrum virucidal efficacy, as well as demonstrated effectiveness against viruses similar to SARS-CoV-2 on hard, non-porous surfaces. For this reason, the PREempt™ line of disinfectants are included on Health Canada’s list of approved disinfectants to be used against SARS-CoV-2 as part of a facility’s COVID-19 infection prevention and control plan (<https://www.canada.ca/en/health-canada/services/drugs-health-products/disinfectants/covid-19/list.html>).

PREempt™ concentrate should be applied at a 1:40 dilution for a contact time of five minutes. PREempt™ ready-to-use liquid and wipes should be applied with a three-minute contact time. Refer to the Public Health Agency of Canada’s website at <https://www.canada.ca/en/public-health.html> for additional information.

Should you require any further information, please do not hesitate to contact me directly at 1-800-387-7578 ext. 118 or via email at nkenny@virox.com.

Best Regards,

Nicole Kenny, HBSc., Assoc Chem
Vice President, Professional and Technical Services
Virox Technologies Inc

